Abstract:
The high mortality rate of HER-2+ve breast cancer (BC) is linked to Trastuzumab resistance, which is linked
to PTEN rs701848 variants. In 160 patients with metastatic HER2+ve BC who were treated with trastuzumab,
the PTEN genotypes were determined. Obtained results revealed that the PTEN locus is a major predictor of
Trastuzumab resistance, and the C allele is linked to a higher risk.
Background: Trastuzumab is an effective therapeutic approach for HER2-positive metastatic breast cancer (BC).
However, a considerable number of patients develop resistance along the course of the disease. PTEN rs701848
polymorphisms are associated with an increased risk of developing cancer and have a potential role in predict-
ing drug resistance. Objective: We studied the significance of PTEN rs701848 variants as significant predictors for
trastuzumab resistance in HER2-positive metastatic BC patients. Therefore, considering their value in predicting clinical
outcomes. Materials and Methods: This case-control study was conducted among female patients with HER2-positive
metastatic breast cancer who underwent Trastuzumab therapy during the period from March 2017 to December 2020.
PTEN rs701848 genotypes were analyzed in 160 HER2-positive metastatic breast cancer who received Trastuzumab
therapy and clinically monitored for therapeutic response. Results: PTEN rs701848 is deemed a significant predictor of
Trastuzumab resistance and an independent prognostic factor of progression-free survival (PPFS). In particular, the C
allele is associated with increased risk for Trastuzumab resistance and shorter PFS as compared to the homozygous
TT genotype. Conclusion: PTEN rs701848 is significant predictor of trastuzumab resistance. Therefore, their value in
predicting clinical outcomes is recommended
Clinical Breast Cancer, Vol. 000, No.xxx, 1–9 © 2022 Elsevier Inc. All rights reserved.
